WINTON GROUP Ltd Invests $570,000 in Penumbra, Inc. (NYSE:PEN)

WINTON GROUP Ltd acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,400 shares of the company's stock, valued at approximately $570,000.

A number of other institutional investors also recently added to or reduced their stakes in PEN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Penumbra in the 4th quarter valued at approximately $573,000. State Street Corp raised its position in Penumbra by 0.3% in the third quarter. State Street Corp now owns 1,236,671 shares of the company's stock worth $240,298,000 after acquiring an additional 3,863 shares in the last quarter. E. Ohman J or Asset Management AB lifted its holdings in Penumbra by 10.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company's stock valued at $5,061,000 after acquiring an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Penumbra by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock worth $64,493,000 after purchasing an additional 3,807 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Penumbra by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company's stock worth $127,417,000 after purchasing an additional 11,257 shares during the period. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Trading Down 2.6 %

Penumbra stock traded down $7.08 during trading on Thursday, reaching $270.27. The company had a trading volume of 123,883 shares, compared to its average volume of 475,386. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The stock's 50 day moving average price is $274.72 and its two-hundred day moving average price is $244.49. The firm has a market capitalization of $10.41 billion, a price-to-earnings ratio of 794.91, a PEG ratio of 2.83 and a beta of 0.51.

Remove Ads

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to analysts' expectations of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, equities analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In related news, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction on Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the transaction, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the sale, the executive vice president now owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,478 shares of company stock worth $26,656,933 in the last three months. 5.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Penumbra from $305.00 to $328.00 and gave the stock an "outperform" rating in a report on Wednesday, February 19th. Citigroup boosted their price target on Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a research note on Wednesday, December 11th. Morgan Stanley raised their price objective on Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 19th. Piper Sandler reiterated an "overweight" rating and set a $330.00 target price (up from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Finally, Oppenheimer began coverage on Penumbra in a research note on Tuesday, December 17th. They set an "outperform" rating and a $275.00 price target for the company. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Penumbra currently has a consensus rating of "Moderate Buy" and a consensus target price of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.